Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients
Autore:
Molina, JM; Cheuc, G; Ferchal, F; Journot, V; Pellegrin, I; Sombardier, MN; Rancinan, C; Cotte, L; Madelaine, I; Debord, T; Decazes, JM;
Indirizzi:
Hop St Louis, Dept Infect Dis, Paris, France Hop St Louis Paris FranceHop St Louis, Dept Infect Dis, Paris, France Hop St Louis, Dept Pharm, Paris, France Hop St Louis Paris FranceHop St Louis, Dept Pharm, Paris, France Hop St Louis, Virol Lab, Paris, France Hop St Louis Paris FranceHop St Louis, Virol Lab, Paris, France INSERM, U330, Dept Epidemiol Publ Hlth & Dev, Bordeaux, France INSERM Bordeaux France Dept Epidemiol Publ Hlth & Dev, Bordeaux, France Hop Pellegrin, Virol Lab, F-33076 Bordeaux, France Hop Pellegrin Bordeaux France F-33076 irol Lab, F-33076 Bordeaux, France Hotel Dieu, Dept Hepatol, Lyon, France Hotel Dieu Lyon FranceHotel Dieu, Dept Hepatol, Lyon, France Hop Begin, Dept Infect Dis, St Mande, France Hop Begin St Mande FranceHop Begin, Dept Infect Dis, St Mande, France
Titolo Testata:
ANTIVIRAL THERAPY
, volume: 4, anno: 1999, supplemento:, 3
pagine: 71 - 74
SICI:
1359-6535(1999)4:<71:ROTATA>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
IMMUNODEFICIENCY-VIRUS INFECTION; CUBIC MILLIMETER; HIV-INFECTION; THERAPY; LAMIVUDINE; ZIDOVUDINE; INDINAVIR;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
12
Recensione:
Indirizzi per estratti:
Indirizzo: Molina, JM Hop St Louis, Dept Infect Dis, Paris, France Hop St Louis Paris France is, Dept Infect Dis, Paris, France
Citazione:
J.M. Molina et al., "Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients", ANTIVIR TH, 4, 1999, pp. 71-74

Abstract

In the ALBI trial, 151 antiretroviral-naive patients with plasma human immunodeficiency virus type 1 (HIV-1) RNA levels of 10000 to 100000 copies/ml and CD4 cell counts greater than or equal to 200 cells/mm(3) received 24 weeks of treatment with stavudine/didanosine (n=51), zidovudine/ lamivudine (n=51) or stavudine/didanosine for 12 weeks followed by zidovudine/lamivudine (n=49). Baseline plasma HIV-1 RNA and CD4 cell counts were comparable in the treatment groups. The mean decrease in plasma HIV-1 RNA at 24 weeks in the stavudine/didanosine group (2.26 log(10)) was significantly greater than that in either the zidovudine/lamivudine group (1.26 log(10)) or the alternating treatment group (1.58 log(10)) (P<0.0001 for bath), Proportions of patients with plasma HIV-1 RNA level <500 copies/ml (91% vs 42% and 60%) and <50 copies/ml (47% versus 4% and 9%) were significantly greater in the stavudine/didanosine group (P<0.001 for pairwise comparisons). Stavudine/didanosine was associated with a mean increase in CD4 cell count (124 cells/mm(3)) significantly greater than that in the zidovudine/lamivudine group (62 cells/mm(3), P<0.01) and comparable to that in the alternating group (118 cells/mm(3)). All study regimens were well tolerated. These findings, indicating superiority of stavudine/didanosine over zidovudine/lamivudine in virological and immunological response over 24 weeks, suggest that the combination should be considered as a basis for highly active antiretroviral therapy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/09/20 alle ore 06:40:27